1
|
Lodi G, Del Re C, Nisticò SP, Bennardo L, Cannarozzo G, Sannino M. Blue light-emitting diodes for the treatment of localized vitiligo: A retrospective study. J Cosmet Dermatol 2022; 22:1273-1278. [PMID: 36575871 DOI: 10.1111/jocd.15567] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2022] [Revised: 11/03/2022] [Accepted: 11/17/2022] [Indexed: 12/29/2022]
Abstract
BACKGROUND Vitiligo is an autoimmune dermatological disease characterized by hypopigmented macules. Treatments include topical agents, phototherapy, and laser therapies. Different lasers should be individually chosen regarding location, extent, activity of the disease. AIMS This article aims to demonstrate how blue LED is effective and safe, as its wavelength is very close to the UV spectrum (415 nm vs. 400 nm), but, unlike UV therapy, blue LED have not shown any long-term cancerogenic side effects. PATIENTS/METHODS We treated 30 patients affected by vitiligo localized on different anatomical areas with blue light-emitting diodes. RESULTS Complete repigmentation occurred in 75.33% of treated patients (22 out of 30 patients, 14 males, and 8 females). Partial repigmentation occurred in the remaining patients. CONCLUSIONS Blue LED light may be a safe and well-tolerated way to induce repigmentation in patients affected by vitiligo.
Collapse
Affiliation(s)
- Giuseppe Lodi
- Laser Unit, University of Rome Tor Vergata, Rome, Italy.,Unit of Dermatology, University of Campania, Naples, Italy
| | - Chiara Del Re
- Department of Health Sciences, University of Magna Graecia, Catanzaro, Italy
| | - Steven Paul Nisticò
- Department of Health Sciences, University of Magna Graecia, Catanzaro, Italy
| | - Luigi Bennardo
- Department of Health Sciences, University of Magna Graecia, Catanzaro, Italy
| | | | - Mario Sannino
- Laser Unit, University of Rome Tor Vergata, Rome, Italy
| |
Collapse
|
2
|
Emerging Skin Toxicities in Patients with Breast Cancer Treated with New Cyclin-Dependent Kinase 4/6 Inhibitors: A Systematic Review. Drug Saf 2021; 44:725-732. [PMID: 33959899 DOI: 10.1007/s40264-021-01071-1] [Citation(s) in RCA: 37] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/15/2021] [Indexed: 12/13/2022]
Abstract
Three cyclin-dependent kinases 4/6, including palbociclib, ribociclib, and abemaciclib, have been approved for the treatment of patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer. The objective of this study was to evaluate the occurrence and clinical spectrum of cutaneous adverse events in patients with breast cancer following therapy with cyclin-dependent kinase 4/6 inhibitors. A systematic literature search was performed in the PubMed, Cochrane, and EMBASE databases up to November 2020 to evaluate studies published from 2015 to 2020. Articles were selected by title, abstract, and full text as required. In addition, a manual search was performed from among the references of articles included. Forty-one articles were included with a total of 13 reported dermatologic reactions including alopecia, bullous skin rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, radiation recall and radiation dermatitis, Henoch-Schonlein purpura, cutaneous leukocytoclastic vasculitis, subacute and chronic cutaneous lupus erythematosus, histiocytoid Sweet syndrome, vitiligo-like lesions, and erythema dyschromicum perstans. Skin toxicity is an important issue because it usually affects a patient's quality of life and could lead to a discontinuation of therapies; therefore, it is of fundamental importance to recognize and adequately manage the adverse skin reactions associated with these types of drugs.
Collapse
|
3
|
Karagaiah P, Valle Y, Sigova J, Zerbinati N, Vojvodic P, Parsad D, Schwartz RA, Grabbe S, Goldust M, Lotti T. Emerging drugs for the treatment of vitiligo. Expert Opin Emerg Drugs 2020; 25:7-24. [PMID: 31958256 DOI: 10.1080/14728214.2020.1712358] [Citation(s) in RCA: 38] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Introduction: Vitiligo is a relatively common autoimmune depigmenting disorder of the skin. There has been a great advance in understanding the pathological basis, which has led to the development and utilization of various new molecules in treating vitiligo. This review aims at a comprehensively describing the treatments available and the emerging treatment aspects and the scope for future developments.Areas covered: This study comprehensively summarizes the current concepts in the pathogenesis of vitiligo with special focus on the cytokine and signaling pathways, which are the targets for newer drugs. JAK kinase signaling pathways and the cytokines involved are the focus of vitiligo treatment in current research, followed by antioxidant mechanisms and repigmenting mechanisms. Topical immunosuppressants may be an alternative to steroids in localized vitiligo. Newer repigmenting agents like basic fibroblast growth factors, afamelanotide have been included and a special emphasis is laid on the upcoming targeted immunotherapy.Expert opinion: The treatment of vitiligo needs to be multimodal with emphasis on targeting different limbs of the pathogenesis. Topical and oral JAK inhibitors are the most promising new class of drugs currently available for treating vitiligo and acts best in conjunction with NB-UVB.
Collapse
Affiliation(s)
- Priyanka Karagaiah
- Department of Dermatology, Bangalore Medical College and Research Institute, Bangalore, India
| | - Yan Valle
- Vitiligo Research Foundation, New York, NY, USA
| | - Julia Sigova
- Pirogov Russian National Research Medical University, Moscow, Russia
| | - Nicola Zerbinati
- Universita degli Studi dell'Insubria Dipartimento di Scienze Chirurgiche e Morfologiche, Varese, Italy
| | - Petar Vojvodic
- Clinic for Mental Disorders "Dr Laza Lazarevic", Belgrade, Serbia
| | | | | | - Stephan Grabbe
- Department of Dermatology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany
| | - Mohamad Goldust
- University of Rome Guglielmo Marconi, Rome, Italy, Department of Dermatology, University Medical Center Mainz, Mainz, Germany
| | - Torello Lotti
- Department of Dermatology, University of Studies Guglielmo Marconi, Rome, Italy
| |
Collapse
|
4
|
El-Zawahry BM, Elmasry MF, Ragab A. The role of long-wavelength ultraviolet A1 (UVA1) in acral vitiligo. J Cosmet Dermatol 2018; 18:1155-1160. [DOI: 10.1111/jocd.12808] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2018] [Revised: 07/17/2018] [Accepted: 10/04/2018] [Indexed: 11/28/2022]
Affiliation(s)
| | - Maha Fathy Elmasry
- Dermatology Department, Faculty of Medicine; Cairo University; Cairo Egypt
| | - Amira Ragab
- Dermatology Department, El Haud El Marsoud Hospital; Cairo Egypt
| |
Collapse
|
5
|
Lotti T, Wollina U, Tchernev G, Valle Y, Lotti J, França K, Satolli F, Rovesti M, Tirant M, Lozev I, Pidakev I, Gianfaldoni S. An Innovative Therapeutic Protocol for Vitiligo: Experience with the Use of Fraxel Herbium Laser, Topical Latanoprost and Successive Irradiation with UVA - 1 Laser. Open Access Maced J Med Sci 2018; 6:49-51. [PMID: 29483980 PMCID: PMC5816313 DOI: 10.3889/oamjms.2018.059] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2017] [Revised: 12/13/2017] [Accepted: 12/14/2017] [Indexed: 12/02/2022] Open
Abstract
Despite the continuous introduction of innovative therapies for vitiligo, today none of them provide constant and excellent results in term of repigmentation. The authors report their experience in treating a localised form of vitiligo with a new protocol consisting in the use of a Fraxel Herbium laser, and in the following application of topical Latanoprost solution and, one day after, in lesional irradiation with UVA1 laser.
Collapse
Affiliation(s)
- Torello Lotti
- University G. Marconi of Rome, Dermatology and Venereology, Rome, Italy
| | - Uwe Wollina
- Städtisches Klinikum Dresden, Department of Dermatology and Venereology, Dresden, Sachsen, Germany
| | - Georgi Tchernev
- Medical Institute of Ministry of Interior Department of General, Vascular and Abdominal Surgery, Sofia, Bulgaria.,Onkoderma - Policlinic for Dermatology and Dermatologic Surgery, Sofia, Bulgaria
| | - Yan Valle
- Vitiligo Research Foundation, New York, United States
| | - Jacopo Lotti
- University G. Marconi of Rome - Dept. of Nuclear, Subnuclear and Radiation Physics, Rome, Italy
| | - Katlein França
- University of Miami School of Medicine, Miami, Florida 33136-1015 United States and Centro Studi per la Ricerca Multidisciplinare e Rigenerativa, Università Degli Studi "G. Marconi", Rome, Italy
| | - Francesca Satolli
- Universita degli Studi di Parma Dipartimento di Medicina Clinica e Sperimentale, Department of Dermatology, University of Parma, Parma, Italy
| | - Miriam Rovesti
- Universita degli Studi di Parma Dipartimento di Medicina Clinica e Sperimentale, Department of Dermatology, University of Parma, Parma, Italy
| | - Michael Tirant
- Psoriasis & Skin Clinic, 374 Nepean Highway Frankston Victoria, Melbourne, Australia
| | - Ilia Lozev
- Medical Institute of Ministry of Interior, Department of General, Vascular and Abdominal Surgery, General Skobelev 79, 1606 Sofia, Bulgaria
| | - Ivan Pidakev
- Medical Institute of Ministry of Interior, Department of General, Vascular and Abdominal Surgery, General Skobelev 79, 1606 Sofia, Bulgaria
| | - Serena Gianfaldoni
- University G. Marconi of Rome - Dermatology and Venereology, University G. Marconi of Rome, Rome, Italy
| |
Collapse
|
6
|
Lotti T, França K. UVA 1 laser in the treatment of patients with vitiligo. Dermatol Ther 2017; 30. [PMID: 28425613 DOI: 10.1111/dth.12494] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2017] [Accepted: 03/24/2017] [Indexed: 11/26/2022]
Affiliation(s)
- Torello Lotti
- Centro Studi per la Ricerca Multidisciplinare Rigenerativa, University of Rome G. Marconi, Rome, Italy
| | - Katlein França
- Centro Studi per la Ricerca Multidisciplinare Rigenerativa, University of Rome G. Marconi, Rome, Italy.,Department of Dermatology & Cutaneous Surgery, Department of Psychiatry & Behavioral Sciences, Institute for Bioethics & Health Policy, University of Miami Miller School of Medicine, Miami, FL
| |
Collapse
|